Waters Stock Price, News & Analysis (NYSE:WAT)

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 1 sell rating and 8 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" WAT shares.
View WAT analyst ratings or view top-rated stocks.

9 analysts have issued 12-month price objectives for Waters' stock. Their WAT share price targets range from $230.00 to $352.00. On average, they anticipate the company's share price to reach $298.00 in the next twelve months. This suggests a possible upside of 4.6% from the stock's current price.
View analysts price targets for WAT or view top-rated stocks among Wall Street analysts.

Waters' stock was trading at $342.58 at the start of the year. Since then, WAT stock has decreased by 16.8% and is now trading at $284.95.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024.
View our WAT earnings forecast.

Waters Co. (NYSE:WAT) released its quarterly earnings results on Tuesday, November, 7th. The medical instruments supplier reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.56 by $0.28. The medical instruments supplier had revenue of $711.69 million for the quarter, compared to the consensus estimate of $722.27 million. Waters had a net margin of 21.80% and a trailing twelve-month return on equity of 102.22%. Waters's revenue was up .4% on a year-over-year basis. During the same period in the prior year, the business posted $2.64 EPS.
Read the conference call transcript.

ETFs with the largest weight of Waters (NYSE:WAT) stock in their portfolio include AXS Cannabis ETF (THCX), Invesco Water Resources ETF (PHO), VictoryShares THB Mid Cap ESG ETF (MDCP), Invesco Global Water ETF (PIO), Motley Fool Mid-Cap Growth ETF (TMFM), Nuveen ESG Mid-Cap Growth ETF (NUMG), Simplify Market Neutral Equity Long/Short ETF (EQLS) and Invesco S&P 500 Equal Weight Health Care ETF (RSPH).

Waters updated its fourth quarter 2023 earnings guidance on Tuesday, November, 7th. The company provided earnings per share guidance of $3.52-$3.62 for the period, compared to the consensus earnings per share estimate of $4.29. The company issued revenue guidance of $807.00 million-$832.75 million, compared to the consensus revenue estimate of $906.36 million.

13 employees have rated Waters Chief Executive Officer Udit Batra on Glassdoor.com. Udit Batra has an approval rating of 100% among the company's employees. This puts Udit Batra in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Waters investors own include Thermo Fisher Scientific (TMO), RTX (RTX), CVS Health (CVS), Home Depot (HD), Johnson & Johnson (JNJ), Abbott Laboratories (ABT), Verizon Communications (VZ), Cisco Systems (CSCO) and Walmart (WMT).

Waters' stock is owned by a number of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (5.96%), Massachusetts Financial Services Co. MA (5.70%), Invesco Ltd. (1.85%), Wellington Management Group LLP (1.78%), American Century Companies Inc. (1.41%) and Impax Asset Management Group plc (1.31%). Insiders that own company stock include Christopher A Kuebler, Edward Conard, Joann A Reed, Linda Baddour, Mark P Vergnano, Michael J Berendt and Thomas P Salice.
View institutional ownership trends.

Shares of WAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.